Article Details
Retrieved on: 2024-07-18 20:21:34
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the MHRA's approval of vibegron for treating overactive bladder (OAB) in adults. The relevance of "business intelligence" lies in how data from the Phase III EMPOWUR trial supports this decision. The tags highlight the specific medical focus and related drugs.
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here